Moderna has secured the European Commission’s go-ahead for its combination flu and COVID-19 vaccine, handing the mRNA specialist a much-needed regulatory win after a rough few months of dealing with the U.S. FDA.

The shot, which will carry the brand name mCOMBRIAX, combines the next-generation COVID-19 vaccine mNEXSPIKE and the investigational flu vaccine mRNA-1010. The European approval covers its use across all 27 European Union member states—plus Iceland, Liechtenstein and Norway—for the active immunization of people 50 years and up, according to a Tuesday company release.